公开(公告)号：US20240285649A1

公开(公告)日：2024-08-29

申请号：US17923539

申请日：2021-05-06

申请人： Shenzhen Evergreen Therapeutics Co., Ltd

发明人： Xin Du ,  Tao Tom Du ,  Weiwei Hua

IPC分类号： A61K31/57 ,  A61K9/48 ,  A61K47/10 ,  A61K47/14 ,  A61P11/00 ,  A61P31/00

CPC分类号： A61K31/57 ,  A61K9/4808 ,  A61K47/10 ,  A61K47/14 ,  A61P11/00 ,  A61P31/00

摘要： Disclosed herein, in certain embodiments, are compositions, solutions, and soft gelatin capsules comprising 17-alpha hydroxyprogesterone caproate (17-HPC). In certain embodiments, also disclosed herein are methods, dosing regimens, and kits for use in the treatment of a disease or condition.

公开(公告)号：US20230020546A1

公开(公告)日：2023-01-19

申请号：US17623331

申请日：2021-03-25

申请人： SHENZHEN EVERGREEN THERAPEUTICS CO., LTD.

发明人： Tao Tom Du ,  Xin Du

IPC分类号： A61K31/57 ,  A61P31/14

摘要： The present application provides a use of hydroxyprogesterone caproate for treating multiple diseases that cause a cytokine storm, such as novel coronavirus pneumonia, various virulent virus infections, side effects after monoclonal antibody treatment, side effects after CAR-T treatment, inflammatory bowel disease, and acute pancreatitis. Moreover, the present application also provides a method for treating the diseases by using a corresponding pharmaceutical composition. Experimental results show that progestin hydroxyprogesterone caproate can effectively inhibit the cytokine storm and is expected to be an effective drug for treating diseases such as novel coronavirus pneumonia.

公开(公告)号：US20240299415A1

公开(公告)日：2024-09-12

申请号：US18549968

申请日：2021-12-01

申请人： Shenzhen Evergreen Therapeutics Co., Ltd

发明人： Tao Tom Du ,  Tao Hu ,  Xin Du

IPC分类号： A61K31/57 ,  A61K31/573 ,  A61P11/00

CPC分类号： A61K31/57 ,  A61K31/573 ,  A61P11/00

摘要： A treatment method for interstitial pneumonia by means of hydroxyprogesterone caproate alone or in combination with other drugs, and corresponding pharmaceutical uses, and pharmaceutical compositions. Hydroxyprogesterone caproate can reduce pulmonary inflammation and fibrosis symptoms, reduce pulmonary collagen deposition, and reduce the levels of various inflammatory factors in bronchoalveolar lavage fluid and plasma. Hydroxyprogesterone caproate combined with dexamethasone can improve lipid metabolism abnormalities caused by dexamethasone treatment alone.

公开(公告)号：US20230181599A1

公开(公告)日：2023-06-15

申请号：US17923532

申请日：2021-05-06

申请人： Shenzhen Evergreen Therapeutics Co., Ltd

发明人： Xin Du ,  Tao Tom Du ,  Weiwei Hua

IPC分类号： A61K31/57 ,  A61K45/06 ,  A61P11/00 ,  A61K9/48

CPC分类号： A61K31/57 ,  A61K45/06 ,  A61P11/00 ,  A61K9/4825

摘要： Disclosed herein, in certain embodiments, are compositions, solutions, and soft gelatin capsules comprising 17-alpha hydroxyprogesterone caproate (17-HPC). In certain embodiments, also disclosed herein are methods, dosing regimens, and kits for use in the treatment of a disease or condition.

公开(公告)号：US20220193092A1

公开(公告)日：2022-06-23

申请号：US17355957

申请日：2021-06-23

申请人： Shenzhen Evergreen Therapeutics Co,. Ltd.

发明人： Tao Hu ,  Tao Tom Du ,  Xin Du

IPC分类号： A61K31/57 ,  A61P37/06

摘要： Disclosed is a method and a composition for inhibiting cytokine storm in a subject in need thereof, in particular cytokine release from PBMCs induced by anti-CD28 antibody and/or anti-CD3 antibody, comprising administering progestogen to the subject. The results show that hydroxyprogesterone caproate could inhibit various cytokines release from PBMC induced by anti-CD28 antibody and/or anti-CD3 antibody in a concentration-dependent manner, and could be a potential drug for the treatment of cytokine storm.